Clearside Biomedical's Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

• Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - "Clearside is leading the way in suprachoroidal delivery, including having the only FDA approved product for suprachoroidal use and a second program with an expected near-term clinical data readout for CLS-AX in the large wet AMD market," said Victor Chong, M.D., MBA, Chief Medical Officer of Clearside. "We believe that suprachoroidal delivery combined with the differentiated mechanism of action and high potency of axi ...